Literature DB >> 7526925

Analysis of mutations and alternative splicing patterns in the CFTR gene using mRNA derived from nasal epithelial cells.

J Hull1, S Shackleton, A Harris.   

Abstract

Ten to fifteen percent of CF chromosomes carry mutations which are not detected by routine screening of the CFTR gene for known mutations. Many techniques have been used to screen the CFTR gene for these remaining mutations. Most of the methods use genomic DNA, and since the CFTR gene contains 27 exons, are necessarily labour intensive. We have screened the entire coding region of CFTR, by chemical cleavage of 7 overlapping segments of amplified cDNA. Using this method we have identified 4 sequence changes which had not been detected by screening genomic DNA, and successfully detected 10 out of 13 known mutations. In addition, we have identified 8 alternatively spliced forms of CFTR mRNA, 4 of which have not been described previously. These include transcripts lacking a) exon 3, b) exons 2 + 3, c) exons 9 + 12, and d) the final 357 bp of exon 15 as a result of use of the cryptic splice donor site CA2863/GTTCGT).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526925     DOI: 10.1093/hmg/3.7.1141

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

2.  In vivo analysis of DNase I hypersensitive sites in the human CFTR gene.

Authors:  D S Moulin; A L Manson; H N Nuthall; D J Smith; C Huxley; A Harris
Journal:  Mol Med       Date:  1999-04       Impact factor: 6.354

3.  Alternative splicing of the ovine CFTR gene.

Authors:  Fiona C Broackes-Carter; Sarah H Williams; Pei Ling Wong; Nathalie Mouchel; Ann Harris
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

4.  Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier.

Authors:  Alexandre Hinzpeter; Abdel Aissat; Elvira Sondo; Catherine Costa; Nicole Arous; Christine Gameiro; Natacha Martin; Agathe Tarze; Laurence Weiss; Alix de Becdelièvre; Bruno Costes; Michel Goossens; Luis J Galietta; Emmanuelle Girodon; Pascale Fanen
Journal:  PLoS Genet       Date:  2010-10-07       Impact factor: 5.917

5.  Reduced splicing efficiency induced by synonymous substitutions may generate a substrate for natural selection of new splicing isoforms: the case of CFTR exon 12.

Authors:  Michela Raponi; Francisco E Baralle; Franco Pagani
Journal:  Nucleic Acids Res       Date:  2006-12-15       Impact factor: 16.971

6.  Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons.

Authors:  Iwona Pranke; Laure Bidou; Natacha Martin; Sandra Blanchet; Aurélie Hatton; Sabrina Karri; David Cornu; Bruno Costes; Benoit Chevalier; Danielle Tondelier; Emmanuelle Girodon; Matthieu Coupet; Aleksander Edelman; Pascale Fanen; Olivier Namy; Isabelle Sermet-Gaudelus; Alexandre Hinzpeter
Journal:  ERJ Open Res       Date:  2018-02-23

7.  CFTR expression from a BAC carrying the complete human gene and associated regulatory elements.

Authors:  George Kotzamanis; Hassan Abdulrazzak; Jennifer Gifford-Garner; Pei Ling Haussecker; Wing Cheung; Catherine Grillot-Courvalin; Ann Harris; Christos Kittas; Athanasios Kotsinas; Vassilis G Gorgoulis; Clare Huxley
Journal:  J Cell Mol Med       Date:  2008-07-24       Impact factor: 5.310

8.  Differential contribution of cis-regulatory elements to higher order chromatin structure and expression of the CFTR locus.

Authors:  Rui Yang; Jenny L Kerschner; Nehal Gosalia; Daniel Neems; Lidija K Gorsic; Alexias Safi; Gregory E Crawford; Steven T Kosak; Shih-Hsing Leir; Ann Harris
Journal:  Nucleic Acids Res       Date:  2015-12-15       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.